Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.35 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.35 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.35 |
| ▸ | ST6GAL1 | P15907 | 6/20 | 0.35 |
| ▸ | NT5E | P21589 | 1/20 | 0.34 |
| ▸ | TYMP | P19971 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 5/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3515586 | 1.00 | LMNA (0.35) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL1054740 | 0.82 | P2RY14 (0.39) | TYMP | |
| SCHEMBL5962131 | 0.82 | P2RY14 (0.39) | TYMP | |
| SCHEMBL5150771 | 0.81 | NT5E (0.51) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL3515581 | 0.80 | TYMP (0.43) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL4338085 | 0.78 | P2RY6 (0.42) | NT5E | |
| SCHEMBL887176 | 0.77 | POLB (0.42) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL1052783 | 0.76 | P2RY14 (0.37) | TYMP | |
| SCHEMBL1050829 | 0.76 | P2RY14 (0.37) | TYMP | |
| SCHEMBL5318031 | 0.75 | ST6GAL1 (0.45) | LMNATHRBMTORMDM2NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1677822-B1 | 4'-THIONUCLEOSIDES AND OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS INC (US) | 2014-04-23 | — | — | EP | disclosed |
| US-20100324277-A1 | OLIGOMERIC COMPOUNDS COMPRISING 4'-THIONUCLEOSIDES FOR USE IN GENE MODULATION | ISIS PHARMACEUTICALS, INC. (US) | 2010-12-23 | — | — | US | disclosed |
| WO-2005027962-A9 | 4’-THIONUCLEOSIDES AND OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS INC (US) | 2006-08-10 | — | — | WO | disclosed |
| US-20050130923-A1 | Nucleosides; RNA interference; gene expression inhibition; for use in therapeutic, diagnostic, and research applications involving gene silencing | IONIS PHARMACEUTICALS, INC. | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324277-A1 | OLIGOMERIC COMPOUNDS COMPRISING 4'-THIONUCLEOSIDES FOR USE IN GENE MODULATION | SNRPE, NSUN3, NSUN2 | LMNA 2015/4885THRB 2388/4885MTOR 3967/4885 |
| US-20050130923-A1 | Nucleosides; RNA interference; gene expression inhibition; for use in therapeutic, diagnostic, and research applications involving gene silencing | NSUN2, SNRPE, SNRPA | LMNA 971/4885THRB 3553/4885MTOR 3904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.